More than a decade of clinical experience on the use of Moxifloxacin in respiratory infections suggests a reappraisal of this last generation fluoroquinolone: in the article it is revisited starting from the rationale of the indication in community acquired pneumonia (CAP) and acute exacerbation of chronic bronchitis (AECB). The important results of all major clinical trials on Moxifloxacin are so re-analyzed, with a particular attention to the study "Mosaic", the first showing in AECB, between two different appropriate antibiotic treatments, the superiority of one over the other. Up to the last study on the CAP, "Motiv", where Moxifloxacin has been proven equivalent to the competitors both in clinical and bacteriological terms. Ultimate information on safety and tolerability are then presented, and in particular the last determinations of the European Agency (EMEA) confirming the indications, with a positive opinion on risk-benefit ratio. The conclusions emphasize the correct use of antibiotics and propose updated algorhythms on the position of Moxifloxacin in the therapy of AECB and CAP.
|Translated title of the contribution||Moxifloxacin: An evergreen fluoroquinolone|
|Number of pages||17|
|Journal||GIMT - Giornale Italiano delle Malattie del Torace|
|Publication status||Published - 2008|
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine